Dato-DXd improved PFS in breast cancer
This announcement contains inside information 22 September 2023 Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive,HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial First Phase III results in breast cancer for AstraZenecaand Daiichi Sankyo's datopotamab deruxtecan Plans for global regulatory submissions underway Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically